NAD+: Research Overview

NAD+ (nicotinamide adenine dinucleotide) is not a peptide at all — it is a coenzyme found in every living cell, central to energy metabolism and to several enzyme families that regulate cellular maintenance. It earns its place in this library because it shares the lyophilized-vial format and research-handling requirements of peptides, and because NAD+ availability has become one of the central variables in cellular-aging and mitochondrial research. Few molecules have a longer scientific history — or a more active modern literature.

A century of biochemistry

NAD+ was discovered in 1906 by Arthur Harden and William John Young during fermentation research — work that contributed to Harden's 1929 Nobel Prize. For most of the 20th century it was understood as a redox cofactor: NAD+ accepts electrons (becoming NADH) in glycolysis and the TCA cycle, then donates them to the electron transport chain — the core chemistry of cellular energy production. That role alone would make it a staple of biochemistry. The modern research wave came from a second discovery: NAD+ is also a consumed substrate for regulatory enzymes.

How NAD+ functions in research models

• Redox cofactor: the NAD+/NADH pair shuttles electrons through central metabolism; cellular energy output in models tracks closely with NAD+ availability.
• Sirtuin substrate: sirtuins (SIRT1–7) — NAD+-dependent deacetylases studied for roles in metabolic regulation, stress response, and chromatin biology — consume NAD+ in every reaction they perform. Sirtuin activity in models is directly gated by NAD+ supply.
• PARP substrate: poly(ADP-ribose) polymerases, the enzymes of DNA-damage response, consume NAD+ when repairing genomes — linking NAD+ to DNA-maintenance research.
• CD38 consumption: the ectoenzyme CD38 degrades NAD+; research (including Camacho-Pereira and colleagues, Cell Metabolism, 2016) identified rising CD38 activity as a driver of age-related NAD+ decline in models.

The age-related decline findings

A consistent literature reports that NAD+ levels fall with age across tissues and species. Human-tissue analyses (Massudi and colleagues, PLoS ONE, 2012) reported significantly lower NAD+ in aged skin; animal studies describe similar declines in liver, muscle, and brain. A landmark mechanistic paper (Gomes and colleagues, Cell, 2013) reported that declining NAD+ with age disrupts nuclear–mitochondrial communication through an HIF-1α-dependent pathway in mice — and that restoring NAD+ with a precursor reversed those molecular markers in aged animals. That paper helped establish NAD+ restoration as a major research direction.

The precursor research wave

Because oral NAD+ itself has limited bioavailability in pharmaceutical research, much of the clinical literature uses precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — which cells convert to NAD+. Published human trials include NR studies (Trammell, Martens and colleagues, Nature Communications, 2016/2018) demonstrating safe NAD+ elevation in humans, and the first published NMN randomized trial (Yoshino and colleagues, Science, 2021), which reported insulin-sensitivity endpoints in a prediabetic research population. Direct NAD+ supplementation remains a distinct research track, examined in cell and infusion-model systems.

Key published findings

• Cell 2013 (Gomes et al.): declining NAD+ disrupted nuclear–mitochondrial signaling in aged mice; precursor-based restoration reversed the measured markers.
• PLoS ONE 2012 (Massudi et al.): human-tissue evidence of age-associated NAD+ decline.
• Science 2021 (Yoshino et al.): first published human NMN randomized trial, reporting metabolic endpoints in the studied population.
• Cell Metabolism 2016 (Camacho-Pereira et al.): CD38 identified as a mechanistic driver of age-related NAD+ decline in models.

Context among related compounds

NAD+ research overlaps with this library's mitochondrial peptides: MOTS-c is a mitochondria-encoded signal, SS-31 stabilizes mitochondrial membranes, and NAD+ is the substrate both systems depend on. The three converge on cellular energy function from different angles and are frequently combined in research designs on mitochondrial health.

What researchers examine

Active questions include NAD+-decline kinetics across tissues, sirtuin and PARP competition for a finite NAD+ pool, CD38-inhibition strategies, precursor-versus-direct supplementation pharmacology, and mitochondrial-function endpoints in aging models. NAD+ is also a baseline control variable in virtually every energy-metabolism research design.

Frequently asked research questions

Is NAD+ a peptide?

No — it is a nucleotide coenzyme. It is supplied in lyophilized vials because it shares the stability and handling requirements of research peptides.

Why do researchers study NAD+ decline?

Published research consistently reports lower NAD+ levels in aged tissues across species, and mechanistic work ties that decline to mitochondrial and sirtuin function — making restoration strategies a major focus of cellular-aging research.

What is the difference between NAD+, NMN, and NR in research?

NMN and NR are precursors that cells convert into NAD+; much of the human-trial literature uses them. Direct NAD+ supplementation is a separate research track examined in cell and infusion-model systems.

Is NAD+ an approved treatment?

No. Material supplied by Prestige Peptides is laboratory research material only, not for human or veterinary use.

How is it supplied and verified?

Lyophilized powder in sealed vials, purity verified by independent third-party analysis.

Why is NAD+ supplied as a lyophilized powder rather than a capsule?

Lyophilized vials suit laboratory handling: exact gravimetric measurement, sterile reconstitution under protocol conditions, and cold-chain stability. The format matches how NAD+ is used in cell and infusion-model research.

How should the research material be stored?

Lyophilized vials: frozen at -20°C or below for long-term storage, protected from light and moisture. After reconstitution under sterile laboratory conditions, keep refrigerated at 2–8°C and use within the protocol's validated window.

How the evidence base reads

NAD+ has the broadest evidence base in this library: a century of biochemistry, consistent cross-species age-decline findings, landmark mechanistic papers (Cell, 2013), and multiple published human precursor trials (Nature Communications 2016/2018; Science 2021). Human data pertain to precursors; direct NAD+ supplementation is a separate, less-developed research track. Supplied material is for laboratory research only.

Laboratory handling and stability

For long-term research storage, keep lyophilized vials frozen at -20°C or below, protected from light and moisture; short-term handling at 2–8°C is standard. Reconstitution should be performed only under sterile laboratory conditions with the laboratory-grade solvent specified by the research protocol, and reconstituted material should be kept cold, protected from light, and used within the validated window of the protocol. Record vial lot numbers and retain the certificate of analysis with study records — traceability is a baseline requirement for reproducible work.

Related research in this library

MOTS-c · SS-31 · Retatrutide

Form, handling, and verification

NAD+ is supplied as a lyophilized (freeze-dried) powder in sealed vials, with identity and purity verified at ≥99% by independent third-party HPLC analysis. Lyophilized material should be stored in a cool, dry environment away from light and handled per standard laboratory protocol with appropriate protective equipment.

View NAD+ research material →

Research Use Only. All materials referenced are supplied strictly for qualified in-vitro laboratory research. Not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any disease. Nothing in this article constitutes medical advice, dosing guidance, or a recommendation for human use.